Target：BCSC-1

Gene Name：VWA5A

Protein Name：von Willebrand factor A domain-containing protein 5A

Human Gene Id：4013

Human Swiss Prot No：O00534

Mouse Swiss Prot No：Q99KC8

Immunogen：The antiserum was produced against synthesized peptide derived from human LHR2A. AA range:371-420

Specificity：BCSC-1 Polyclonal Antibody detects endogenous levels of BCSC-1 protein.

Formulation：Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source：Polyclonal, Rabbit,IgG

Dilution：WB 1:500 - 1:2000. ELISA: 1:20000. Not yet tested in other applications.

Purification：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration：1 mg/ml

Storage Stability：-15°C to -25°C/1 year(Do not lower than -25°C)

Other Name：VWA5A;BCSC1;LOH11CR2A;von Willebrand factor A domain-containing protein 5A;Breast cancer suppressor candidate 1;BCSC-1;Loss of heterozygosity 11 chromosomal region 2 gene A protein

Observed Band(KD)：86kD

Background：VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80% of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A. Existing as four alternatively spliced isoforms, the gene encoding VWA5A maps to human chromosome 11q24.2.

Subcellular Location：nucleus,nucleoplasm,

Expression：Expressed at low level in many tissues. Not expressed in 80% of tumor cell lines tested.